174 related articles for article (PubMed ID: 36842319)
1. Design, synthesis and bioactivity evaluation of self-assembled PROTACs based on multi-target kinase inhibitors.
Si R; Zhu H; Wang J; Zhang Q; Li Y; Pan X; Zhang J
Bioorg Chem; 2023 May; 134():106439. PubMed ID: 36842319
[TBL] [Abstract][Full Text] [Related]
2. Discovery of novel protein degraders based on bioorthogonal reaction-driven intracellular self-assembly strategy.
Si R; Zhu H; Wang J; Zhang Q; Li Y; Pan X; Zhang J
Bioorg Chem; 2023 Jun; 135():106497. PubMed ID: 37003135
[TBL] [Abstract][Full Text] [Related]
3. Discovery of intracellular self-assembly protein degraders driven by tumor-specific activatable bioorthogonal reaction.
Si R; Hai P; Zheng Y; Wang J; Zhang Q; Li Y; Pan X; Zhang J
Eur J Med Chem; 2023 Sep; 257():115497. PubMed ID: 37216813
[TBL] [Abstract][Full Text] [Related]
4. PROTACS: A technology with a gold rush-like atmosphere.
Wang YW; Lan L; Wang M; Zhang JY; Gao YH; Shi L; Sun LP
Eur J Med Chem; 2023 Feb; 247():115037. PubMed ID: 36566716
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of KRAS
Zhang X; Zhao T; Sun M; Li P; Lai M; Xie L; Chen J; Ding J; Xie H; Zhou J; Zhang H
Bioorg Med Chem; 2023 Jan; 78():117153. PubMed ID: 36621179
[TBL] [Abstract][Full Text] [Related]
6. Integrated Direct-to-Biology Platform for the Nanoscale Synthesis and Biological Evaluation of PROTACs.
Stevens R; Bendito-Moll E; Battersby DJ; Miah AH; Wellaway N; Law RP; Stacey P; Klimaszewska D; Macina JM; Burley GA; Harling JD
J Med Chem; 2023 Nov; 66(22):15437-15452. PubMed ID: 37933562
[TBL] [Abstract][Full Text] [Related]
7. In situ albumin-binding and esterase-specifically cleaved BRD4-degrading PROTAC for targeted cancer therapy.
Cho H; Jeon SI; Shim MK; Ahn CH; Kim K
Biomaterials; 2023 Apr; 295():122038. PubMed ID: 36787659
[TBL] [Abstract][Full Text] [Related]
8. Persistent Degradation of HER2 Protein by Hybrid nanoPROTAC for Programmed Cell Death.
Wang Z; Tan M; Su W; Huang W; Zhang J; Jia F; Cao G; Liu X; Song H; Ran H; Nie G; Wang H
J Med Chem; 2023 May; 66(9):6263-6273. PubMed ID: 37092695
[TBL] [Abstract][Full Text] [Related]
9. Drug delivery challenges and formulation aspects of proteolysis targeting chimera (PROTACs).
Saraswat AL; Vartak R; Hegazy R; Patel A; Patel K
Drug Discov Today; 2023 Jan; 28(1):103387. PubMed ID: 36184017
[TBL] [Abstract][Full Text] [Related]
10. PROTACs to address the challenges facing small molecule inhibitors.
Martín-Acosta P; Xiao X
Eur J Med Chem; 2021 Jan; 210():112993. PubMed ID: 33189436
[TBL] [Abstract][Full Text] [Related]
11. Ugi reaction-assisted assembly of covalent PROTACs against glutathione peroxidase 4.
Zhu L; Hu S; Yan X; Zeng Q; Zhang B; Jiang L; Yao SQ; Ge J
Bioorg Chem; 2023 May; 134():106461. PubMed ID: 36924654
[TBL] [Abstract][Full Text] [Related]
12. Folate-PEG-PROTAC Micelles for Enhancing Tumor-Specific Targeting Proteolysis In Vivo.
Ma J; Fang L; Sun Z; Li M; Fan T; Xiang G; Ma X
Adv Healthc Mater; 2024 Apr; ():e2400109. PubMed ID: 38676445
[TBL] [Abstract][Full Text] [Related]
13. Discovery of selective platelet-derived growth factor receptor-beta (PDGFR-β) bifunctional small-molecule degraders.
Si R; Liu N; Wang J; Zhang Q; Li Y; Pan X; Zhang J
Bioorg Med Chem; 2023 Jan; 77():117115. PubMed ID: 36508995
[TBL] [Abstract][Full Text] [Related]
14. Small-molecule PROTACs: novel agents for cancer therapy.
Wan Y; Yan C; Gao H; Liu T
Future Med Chem; 2020 May; 12(10):915-938. PubMed ID: 32270707
[TBL] [Abstract][Full Text] [Related]
15. Rational Design of Bioorthogonally Activatable PROTAC for Tumor-Targeted Protein Degradation.
Bi T; Liang P; Zhou Y; Wang H; Huang R; Sun Q; Shen H; Yang S; Ren W; Liu Z
J Med Chem; 2023 Nov; 66(21):14843-14852. PubMed ID: 37871321
[TBL] [Abstract][Full Text] [Related]
16. Development of the nonreceptor tyrosine kinase FER-targeting PROTACs as a potential strategy for antagonizing ovarian cancer cell motility and invasiveness.
Zhang Y; Xiong X; Sun R; Zhu X; Wang C; Jiang B; Yang X; Li D; Fan G
J Biol Chem; 2023 Jun; 299(6):104825. PubMed ID: 37196766
[TBL] [Abstract][Full Text] [Related]
17. Sulfatase-Induced In Situ Formulation of Antineoplastic Supra-PROTACs.
Chen N; Zhang Z; Liu X; Wang H; Guo RC; Wang H; Hu B; Shi Y; Zhang P; Liu Z; Yu Z
J Am Chem Soc; 2024 Apr; 146(15):10753-10766. PubMed ID: 38578841
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of the tumor hypoxia-activated PROTACs bearing caged CRBN E3 ligase ligands.
Cheng W; Li S; Han S; Miao R; Wang S; Liu C; Wei H; Tian X; Zhang X
Bioorg Med Chem; 2023 Mar; 82():117237. PubMed ID: 36906965
[TBL] [Abstract][Full Text] [Related]
19. Discovery of the GSH responsive "Y-PROTACs" targeting ALK and CDK4/6 as a potential treatment for cancer.
Wang S; Luo D; Pu C; Ma X; Zhang H; Feng Z; Deng R; Yu S; Liu Y; Huang Q; Li R
Eur J Med Chem; 2023 Feb; 248():115082. PubMed ID: 36628851
[TBL] [Abstract][Full Text] [Related]
20. The application of PROTAC in HDAC.
Chen S; Zheng Y; Liang B; Yin Y; Yao J; Wang Q; Liu Y; Neamati N
Eur J Med Chem; 2023 Nov; 260():115746. PubMed ID: 37607440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
